Sarah Kane, Ph.D.
GT Molecular
Sarah Kane received her Ph.D. in cell and molecular biology from Colorado State University. While her doctoral and postdoctoral projects primarily focused on prion diseases, Kane maintains interest in various fields spanning immunology, infectious disease and neuroscience.
Kane joined GT Molecular’s growing research and development team early during the COVID-19 pandemic to develop PCR assays and validate GT Molecular’s national wastewater testing service. Currently, and throughout the pandemic, she and other team members design and validate PCR kits capable of detecting and calculating abundance of SARS-CoV-2 variants from wastewater that represents an average, community-wide sample. Kane currently serves as Director of R&D, where she oversees projects using GT Molecular’s patent-pending technology around multiplexed digital PCR and NGS assay development for cancer and pathogen detection both in clinical and WBE settings. She ultimately holds passion for generating data for action.
Kane joined GT Molecular’s growing research and development team early during the COVID-19 pandemic to develop PCR assays and validate GT Molecular’s national wastewater testing service. Currently, and throughout the pandemic, she and other team members design and validate PCR kits capable of detecting and calculating abundance of SARS-CoV-2 variants from wastewater that represents an average, community-wide sample. Kane currently serves as Director of R&D, where she oversees projects using GT Molecular’s patent-pending technology around multiplexed digital PCR and NGS assay development for cancer and pathogen detection both in clinical and WBE settings. She ultimately holds passion for generating data for action.